A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors.
A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors.
复制标题
异种移植前列腺肿瘤中肿瘤起始细胞的新型体外测定。
DOI：
10.1002/pros.21171
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Palapattu,GaneshS
中科院分区：
文献类型：
--
作者：
Silvers,ChristopherR;Williams,Karin;Salamone,Linda;Huang,Jiaoti;Jordan,CraigT;Zhou,Haijun;Palapattu,GaneshS
BACKGROUNDThe field of prostate cancer has been stymied by the difficulty of cultivating patient‐derived samples in the laboratory. In order to help circumvent this challenge, we sought to develop an in vitro assay of human prostate cancer initiation employing a prostate‐associated mesenchymal feeder layer.METHODSRat seminal vesicle mesenchyme (rSVM) harvested from male neonatal rats was plated in 12‐well plates and then irradiated with 30 Gy after ∼75% confluence. Single‐cell suspensions of two human non‐adherent prostate cancer xenograft lines (TRPC and LAPC9) were then plated on irradiated rSVM. At 3–4 weeks, three‐dimensional solid structures, termed glandoids, were harvested and analyzed or transplanted singly into the renal capsule of immunodeficient mice. Animals were assessed for tumor formation 8–12 weeks after engraftment. Finally, clonality assays were performed to determine whether glandoids usually arise from a single cell and are therefore clonal in origin.RESULTSGlandoids form with reliable frequency (1/∼300 plated cells), are constituted by relevant cell types (CK8+, CK5−, PSA+) and after implantation into immunocompromised mice, give rise to tumors that recapitulate original xenograft histology and cell composition; defining a glandoid as a tumor‐initiating unit. In addition, assessment of red fluorescent protein (RFP)‐labeled glandoids revealed either all red or non‐red structures, with few areas of fusion, suggesting glandoids are clonal in origin.CONCLUSIONSThe above assay describes an adjunct technique to readily cultivate cells from prostate cancer xenografts in vitro and as such provides a platform on which tumor‐initiating cell studies and high‐throughput drug discovery may be performed. Prostate 70: 1379–1387, 2010. © 2010 Wiley‐Liss, Inc.
